The role of the cerebellum in schizophrenia: from cognition to molecular pathways

Imagem de Miniatura
Arquivos
art_YEGANEH-DOOST_The_role_of_the_cerebellum_in_schizophrenia_from_2011.PDF (932.23 KB)
Citações na Scopus
90
Tipo de produção
article
Data de publicação
2011
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
YEGANEH-DOOST, Peyman
GRUBER, Oliver
FALKAI, Peter
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICS, v.66, suppl.1, p.71-77, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Beside its role in motor coordination, the cerebellum is involved in cognitive function such as attention, working memory, verbal learning, and sensory discrimination. In schizophrenia, a disturbed prefronto-thalamo-cerebellar circuit has been proposed to play a role in the pathophysiology. In addition, a deficit in the glutamatergic N-methyl-D-aspartate (NMDA) receptor has been hypothesized. The risk gene neuregulin 1 may play a major role in this process. We demonstrated a higher expression of the NMDA receptor subunit 2D in the right cerebellar regions of schizophrenia patients, which may be a secondary upregulation due to a dysfunctional receptor. In contrast, the neuregulin 1 risk variant containing at least one C-allele was associated with decreased expression of NMDA receptor subunit 2C, leading to a dysfunction of the NMDA receptor, which in turn may lead to a dysfunction of the gamma amino butyric acid (GABA) system. Accordingly, from post-mortem studies, there is accumulating evidence that GABAergic signaling is decreased in the cerebellum of schizophrenia patients. As patients in these studies are treated with antipsychotics long term, we evaluated the effect of long-term haloperidol and clozapine treatment in an animal model. We showed that clozapine may be superior to haloperidol in restoring a deficit in NMDA receptor subunit 2C expression in the cerebellum. We discuss the molecular findings in the light of the role of the cerebellum in attention and cognitive deficits in schizophrenia.
Palavras-chave
Schizophrenia, Cerebellum, N-methyl D-aspartate receptor, Gamma amino butyric acid, Antipsychotics
URI
https://observatorio.fm.usp.br/handle/OPI/24093
Referências
  1. Albus M, 2002, EUR ARCH PSY CLIN N, V252, P262, DOI 10.1007/s00406-002-0391-4
  2. Andreasen NC, 2008, SCHIZOPHRENIA BULL, V34, P708, DOI 10.1093/schbul/sbn034
  3. Andreasen NC, 2009, SCHIZOPHRENIA BULL, V35, P1030, DOI 10.1093/schbul/sbp069
  4. ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669
  5. Ichimiya T, 2001, BIOL PSYCHIAT, V49, P20, DOI 10.1016/S0006-3223(00)01081-7
  6. Albus M, 2006, EUR ARCH PSY CLIN N, V256, P442, DOI 10.1007/s00406-006-0667-1
  7. Andreasen NC, 2008, BIOL PSYCHIAT, V64, P81, DOI 10.1016/j.biopsych.2008.01.003
  8. Volz HP, 2000, SCHIZOPHR RES, V46, P45, DOI 10.1016/S0920-9964(99)00236-4
  9. Eastwood SL, 2000, MOL PSYCHIATR, V5, P425, DOI 10.1038/sj.mp.4000741
  10. Jentsch JD, 1999, NEUROPSYCHOPHARMACOL, V20, P201, DOI 10.1016/S0893-133X(98)00060-8
  11. Bullock WM, 2009, NEUROCHEM INT, V55, P775, DOI 10.1016/j.neuint.2009.07.010
  12. Hoff AL, 2005, SCHIZOPHR RES, V78, P27, DOI 10.1016/j.schres.2005.05.010
  13. Maloku E, 2010, P NATL ACAD SCI USA, V107, P4407, DOI 10.1073/pnas.0914483107
  14. Okugawa G, 2002, SCHIZOPHR RES, V55, P61, DOI 10.1016/S0920-9964(01)00248-1
  15. Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545
  16. MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0
  17. Law AJ, 2006, P NATL ACAD SCI USA, V103, P6747, DOI 10.1073/pnas.0602002103
  18. Andreasen NC, 1999, BIOL PSYCHIAT, V46, P908, DOI 10.1016/S0006-3223(99)00152-3
  19. Picard H, 2008, SCHIZOPHRENIA BULL, V34, P155, DOI 10.1093/schbul/sbm049
  20. Bullock WM, 2008, AM J PSYCHIAT, V165, P1594, DOI 10.1176/appi.ajp.2008.07121845
  21. Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734
  22. Davis KL, 2003, ARCH GEN PSYCHIAT, V60, P443, DOI 10.1001/archpsyc.60.5.443
  23. Andreasen NC, 2005, AM J PSYCHIAT, V162, P441, DOI 10.1176/appi.ajp.162.3.441
  24. ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P784
  25. HEINRICHS DW, 1988, AM J PSYCHIAT, V145, P11
  26. KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851
  27. Ozaki M, 1997, NATURE, V390, P691
  28. Bakker SC, 2004, MOL PSYCHIATR, V9, P1061, DOI 10.1038/sj.mp.4001564
  29. Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740
  30. MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102
  31. Georgieva L, 2008, BIOL PSYCHIAT, V64, P419, DOI 10.1016/j.biopsych.2008.03.025
  32. Haarmeier T, 2007, CEREBELLUM, V6, P177, DOI 10.1080/14734220701286187
  33. Schmitt A, 2003, NEUROCHEM RES, V28, P235, DOI 10.1023/A:1022325116309
  34. Deng MY, 2009, PSYCHOPHARMACOLOGY, V206, P437, DOI 10.1007/s00213-009-1619-z
  35. AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037//0735-7044.106.5.731
  36. Fuentes CT, 2007, CEREBELLUM, V6, P232, DOI 10.1080/14734220701329268
  37. Gruber O, 2006, NEUROSCI LETT, V405, P24, DOI 10.1016/j.neulet.2006.06.062
  38. Winterer G, 2008, NEUROIMAGE, V40, P712, DOI 10.1016/j.neuroimage.2007.12.041
  39. Gruber O, 2003, NEUROIMAGE, V19, P797, DOI 10.1016/S1053-8119(03)00089-2
  40. Guidotti A, 2000, NEUROCHEM RES, V25, P1207, DOI 10.1023/A:1007635927069
  41. CHEN EYH, 1995, PSYCHIAT RES, V56, P183, DOI 10.1016/0165-1781(95)02535-2
  42. Molinari M, 2007, CEREBELLUM, V6, P214, DOI 10.1080/14734220701230870
  43. Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558
  44. Stefansson H, 2003, AM J HUM GENET, V72, P83, DOI 10.1086/345442
  45. Schmitt A, 2009, ACTA NEUROPATHOL, V117, P395, DOI 10.1007/s00401-008-0430-y
  46. Henseler I, 2009, EUR J NEUROSCI, V30, P693, DOI 10.1111/j.1460-9568.2009.06850.x
  47. Gruber O, 2001, CEREB CORTEX, V11, P1047, DOI 10.1093/cercor/11.11.1047
  48. Henseler I, 2010, J PSYCHIATR RES, V44, P364, DOI 10.1016/j.jpsychires.2009.09.003
  49. Carlsson A, 1999, EUR ARCH PSY CLIN N, V249, P37
  50. Keedy SK, 2009, PSYCHIAT RES-NEUROIM, V172, P16, DOI 10.1016/j.pscychresns.2008.06.003
  51. Robinson DG, 2002, SCHIZOPHR RES, V57, P209, DOI 10.1016/S0920-9964(01)00312-7
  52. Bellebaum C, 2007, CEREBELLUM, V6, P184, DOI 10.1080/14734220601169707
  53. Eastwood SL, 2001, NEUROSCIENCE, V105, P219, DOI 10.1016/S0306-4522(01)00141-5
  54. MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688
  55. ISHII T, 1993, J BIOL CHEM, V268, P2836
  56. Fatemi SH, 2005, SCHIZOPHR RES, V72, P109, DOI 10.1016/j.schres.2004.02.017
  57. Honer WG, 2002, CEREB CORTEX, V12, P349, DOI 10.1093/cercor/12.4.349
  58. Yang JZ, 2003, MOL PSYCHIATR, V8, P706, DOI 10.1038/sj.mp.4001377
  59. Ackermann H, 2007, CEREBELLUM, V6, P202, DOI 10.1080/14734220701266742
  60. Akbarian S, 1996, J NEUROSCI, V16, P19
  61. Baillieux H, 2008, CLIN NEUROL NEUROSUR, V110, P496, DOI 10.1016/j.clineuro.2008.01.003
  62. Ben-Yehudah G, 2007, CEREBELLUM, V6, P193, DOI 10.1080/14734220701286195
  63. Bramon E, 2008, SCHIZOPHR RES, V103, P178, DOI 10.1016/j.schres.2008.03.025
  64. Carlsson A, 1995, INT CLIN PSYCHOPHARM, V10, P21, DOI 10.1097/00004850-199509000-00004
  65. Courchesne E, 1995, Electroencephalogr Clin Neurophysiol Suppl, V44, P315
  66. COURCHESNE E, 1994, BEHAV NEUROSCI, V108, P848, DOI 10.1037//0735-7044.108.5.848
  67. CROW TJ, 1980, BRIT MED J, V280, P66
  68. Cull-Candy SG, 1998, NEUROPHARMACOLOGY, V37, P1369, DOI 10.1016/S0028-3908(98)00119-1
  69. Deicken RF, 2001, PSYCHIAT RES-NEUROIM, V107, P125, DOI 10.1016/S0925-4927(01)00103-2
  70. Ende G, 2005, AM J PSYCHIAT, V162, P790, DOI 10.1176/appi.ajp.162.4.790
  71. Farber NB, 1999, ARCH GEN PSYCHIAT, V56, P13, DOI 10.1001/archpsyc.56.1.13
  72. FARBER NB, 2000, ARCH GEN PSYCHIAT, V57, P1181, DOI 10.1001/ARCHPSYC.57.12.1165
  73. Fatemi SH, 2005, SCHIZOPHR RES, V74, P287, DOI 10.1016/j.schres.2004.12.001
  74. Glantz LA, 1997, ARCH GEN PSYCHIAT, V54, P660
  75. GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1
  76. Gruber O, 2005, RADIOLOGE, V45, P153, DOI 10.1007/s00447-004-1155-0
  77. Gruber O, 2006, NEUROIMAGE, V31, P887, DOI 10.1016/j.neuroimage.2005.12.043
  78. Gruber O, 2011, EUR ARCH PSY CLIN N, V261, P179, DOI 10.1007/s00406-010-0165-3
  79. Gruber O, 2008, J PSYCHIATR RES, V43, P1, DOI 10.1016/j.jpsychires.2008.01.009
  80. Gruber O, 2010, HUM BRAIN MAPP, V31, P115, DOI 10.1002/hbm.20849
  81. Gruber O, 2009, NERVENARZT, V80, P12, DOI 10.1007/s00115-008-2615-y
  82. Hafner H., 2003, SCHIZOPHRENIA, P101
  83. Hänninen Kari, 2008, Eur Arch Psychiatry Clin Neurosci, V258, P10
  84. Harrison PJ, 2005, MOL PSYCHIATR, V10, P804, DOI 10.1038/sj.mp.4001686
  85. HARRISON PJ, 2005, MOL PSYCHIATR, V10, P4420
  86. Hoff AL, 1996, SCHIZOPHR RES, V20, P21, DOI 10.1016/0920-9964(95)00065-8
  87. Hubrich-Ungureanu P, 2002, NEUROSCI LETT, V319, P91, DOI 10.1016/S0304-3940(01)02566-6
  88. JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301
  89. Kampman O, 2004, NEUROREPORT, V15, P2517, DOI 10.1097/00001756-200411150-00017
  90. Kircher T, 2009, EUR ARCH PSY CLIN N, V259, P72, DOI 10.1007/s00406-008-0837-4
  91. Klingberg T, 1996, EUR J NEUROSCI, V8, P1965, DOI 10.1111/j.1460-9568.1996.tb01340.x
  92. Konarski JZ, 2005, J PSYCHIATR NEUROSCI, V30, P178
  93. LEVY DL, 1994, SCHIZOPHRENIA BULL, V20, P47
  94. OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998
  95. Parlapani E, 2010, WORLD J BIOL PSYCHIA, V11, P243, DOI 10.3109/15622970802022376
  96. Scherzer CR, 1997, NEUROBIOL DIS, V4, P35, DOI 10.1006/nbdi.1997.0136
  97. Schmitt A, 2008, EUR ARCH PSY CLIN N, V258, P35, DOI 10.1007/s00406-008-5019-x
  98. Schmitt A, 2001, FORTSCHR NEUROL PSYC, V69, P105, DOI 10.1055/s-2001-12277
  99. Schmitt A, 2010, EUR ARCH PSY CLIN N, V260, P101, DOI 10.1007/s00406-009-0017-1
  100. SURGULADZE SA, 2010, J PSYCHOPHARMACO APR
  101. Thach WT, 2007, CEREBELLUM, V6, P163, DOI 10.1080/14734220701373530
  102. Thaker GK, 2000, SCHIZOPHR RES, V45, P235, DOI 10.1016/S0920-9964(99)00193-0
  103. THOMANN PA, 2008, PSYCHOL MED, V39, P371, DOI 10.1017/S0033291708003656
  104. Venkatasubramanian G, 2008, PSYCHIAT RES-NEUROIM, V164, P215, DOI 10.1016/j.pscychresns.2007.12.021
  105. Weinberger DR, 1996, NEUROPSYCHOPHARMACOL, V14, P1
  106. Zilles D, 2009, EUR ARCH PSY CLIN N, V259, P309, DOI 10.1007/s00406-009-0001-9
  107. Zilles D, 2010, EUR ARCH PSY CLIN N, V260, P519, DOI 10.1007/s00406-010-0107-0

Coleções
Artigos e Materiais de Revistas Científicas - LIM/27